Navigation Links
Aratana Therapeutics Adds to Commercial Leadership Team
Date:10/24/2013

na Therapeutics

Aratana Therapeutics is a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Forward-Looking Statements Disclaimer

 This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the expansion of our commercial infrastructure; expectations regarding development programs, trials, studies, and approval; expectations regarding in-license initiatives; and expectations regarding the Company's plans and opportunities. 

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history and expectations of loss
'/>"/>

SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Aratana Therapeutics names Wendy Yarno to its Board of Directors
2. Aratana Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
3. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
4. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
5. Aratana Therapeutics Reports Second Quarter 2013 Financial Results
6. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
7. Aratana Therapeutics to Present at Two Upcoming Healthcare Conferences
8. Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
9. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
10. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
11. Aratana to Participate in Leerink Swanns November Management Access Days
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... The Competitive Intelligence (CI) function is evolving ... leaders who adjust will succeed, and those who don,t ... Practices, LLC study CI leaders from 32 biopharmaceutical organizations ... - Use secondary research whenever possible - it,s effective, ... Internal staff who are creative thinkers provide the CI ...
(Date:8/29/2014)... , Aug. 29, 2014   Mast ... biopharmaceutical company, announced today that Santosh Vetticaden, Chief ... leaving the Company, for personal reasons, in mid-September.  ... Medical Officer of Aires Pharmaceuticals, which Mast acquired ... responsibilities as the Company,s interim Chief Medical Officer.  ...
(Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Benefiting ... for medical expenses, the Chinese orthopedic instrument market demand ... CAGR of 19.2% during 2009-2013. Trauma products, spine products ... instruments in China , of which ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... of bortezomib-relapsed patient population demonstrates 55% overall response ... 26 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... an ongoing Phase 1/2 study of KRX-0401 (perifosine) ... with relapsed/refractory multiple myeloma. The data, which was ...
... ExonHit Therapeutics,(Alternext: ALEHT) is pleased to announce that clinical ... is progressing well. Patient,enrolment for the Phase IIa trial ... , "The successful completion of ... in the development of EHT 0202, and,provides a clear ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting 4ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 2ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 3ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 4
(Date:8/30/2014)... Continuing to meet the skin health needs ... addition of a new doctor and office in Grand ... skin care in Grand Rapids since 1980 is merging ... doctor, my passion is making sure my patients receive ... I’m better able to focus on my patients and ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 "My wife ... of a car accident," said one of two inventors ... strain in her shoulder and neck area. She tried ... reduced pain and pressure, assisting in comfort and providing ... patent-pending PILLOW CRADLE to support the head, neck and ...
(Date:8/30/2014)... Serving contented clients since inception, #1 web design ... is now offering discount for Labor Day on all ... putting forward the best of web development technology before ... of professionals and web developers and designers has expertise ... critical issues of web development and can develop websites ...
(Date:8/30/2014)... August 2014: Transvenous lead extraction (TLE) is clinically successful ... from the European Lead Extraction ConTRolled (ELECTRa) registry presented ... by Dr Maria Grazia Bongiorni, chair of the registry,s ... cardiac implantable electronic devices (CIED) implant procedures has grown ... of complications has increased and leads are often the ...
(Date:8/30/2014)... August 30, 2014 Top10BestSEOHosting.com is ... researchers have announced that HostGator.com http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... current market. Also, they has announced that Bluehost ... , Hostgator, one of the Top 10 ... of cheap Windows hosting, and it offers rich ...
Breaking Medicine News(10 mins):Health News:Expanding Care at the Forefront of Dermatology 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2
... Approximately sixty-five state and local public health laboratories ... confirmatory testing of Human Influenza A H1N1 of Swine ... all swine flu specimens had to be sent to ... identifies specimens to the strain level.The rRT-PCR swine flu ...
... Approved Simponi is Expected to Achieve Strong ... a New Report from Decision ResourcesWALTHAM, Mass., ... the world,s leading research and advisory firms ... the availability of Amgen/Wyeth/Takeda,s Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe,s ...
... Justice grant creates federal-state-local partnership to help fight ... A sweeping $1.1 million U.S. Justice Dept. grant ... prosecution agency to help combat domestic violence and ... State,s Attorney,s Appellate Prosecutor,s office has hired two ...
... promise in study , , THURSDAY, April 30 (HealthDay News) ... multiple sclerosis (MS) drug may give patients more relief ... a new study. , In the study, which included ... selected to receive the steroid drug methylprednisolone in three ...
... After surgery to remove the head of the pancreas, ... in a lower rate of pancreatic fistula, according to ... Center. The research was published in the Journal ... performed as a randomized trial the gold standard ...
... up 266%, , ... Winston-Salem, NC ... that it is expanding its corporate and satellite offices to ... system, VerteLoc™. , , , , ,"We are essentially doubling ...
Cached Medicine News:Health News:Public Health Laboratories To Assume Primary Responsibility for Confirmatory Testing of Swine Flu 2Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 2Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 3Health News:New Illinois Prosecution Unit Helps Protect Women Against Violence 2Health News:Drug Combo May Relieve MS Symptoms 2Health News:Type of connection procedure after pancreatic surgery influenced rate of pancreatic fistula 2Health News:VGI Announces Expansion to Meet Surgeon Demand for the VerteLoc™ Spine Stabilization System 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: